Telo Genomics Statistics

Total Valuation

Telo Genomics has a market cap or net worth of CAD 4.02 million. The enterprise value is 3.53 million.

Market Cap	4.02M
Enterprise Value	3.53M

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Telo Genomics has 100.43 million shares outstanding. The number of shares has increased by 30.48% in one year.

Current Share Class	100.43M
Shares Outstanding	100.43M
Shares Change (YoY)	+30.48%
Shares Change (QoQ)	+0.41%
Owned by Insiders (%)	2.95%
Owned by Institutions (%)	0.10%
Float	97.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	-150.44
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.30
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.63

Financial Position

The company has a current ratio of 0.93

Current Ratio	0.93
Quick Ratio	0.79
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-557.25

Financial Efficiency

Return on equity (ROE) is -52,000.65% and return on invested capital (ROIC) is -32,246.03%.

Return on Equity (ROE)	-52,000.65%
Return on Assets (ROA)	-320.71%
Return on Invested Capital (ROIC)	-32,246.03%
Return on Capital Employed (ROCE)	10,060.22%
Weighted Average Cost of Capital (WACC)	4.44%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	6
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.33% in the last 52 weeks. The beta is 0.04, so Telo Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.04
52-Week Price Change	-73.33%
50-Day Moving Average	0.05
200-Day Moving Average	0.08
Relative Strength Index (RSI)	41.36
Average Volume (20 Days)	73,601

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-2.69M
Pretax Income	-2.71M
Net Income	-2.71M
EBITDA	-2.67M
EBIT	-2.69M
Earnings Per Share (EPS)	-0.03

Full Income Statement

Balance Sheet

The company has 486,508 in cash and n/a in debt, with a net cash position of 486,508 or 0.00 per share.

Cash & Cash Equivalents	486,508
Total Debt	n/a
Net Cash	486,508
Net Cash Per Share	0.00
Equity (Book Value)	-26,704
Book Value Per Share	-0.00
Working Capital	-45,054

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.16 million and capital expenditures -5,325, giving a free cash flow of -2.17 million.

Operating Cash Flow	-2.16M
Capital Expenditures	-5,325
Free Cash Flow	-2.17M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Telo Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.48%
Shareholder Yield	-30.48%
Earnings Yield	-67.40%
FCF Yield	-53.95%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 22, 2019. It was a reverse split with a ratio of 0.2.

Last Split Date	Nov 22, 2019
Split Type	Reverse
Split Ratio	0.2

Scores

Altman Z-Score	n/a
Piotroski F-Score	1